Litcius/Paper detail

Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers

Di Zhang, Qi‐Fang Huang, Chang‐Sheng Sheng, Li Y, Ji‐Guang Wang

2021Blood Pressure17 citationsDOIOpen Access PDF

Abstract

PURPOSE: We investigated serum uric acid changes in relation to the achieved clinic and ambulatory blood pressure after 8 weeks of antihypertensive therapy with two dihydropyridine calcium channel blockers. MATERIALS AND METHODS: = 203). Hyperuricaemia was defined as a serum uric acid concentration of ≥420 µmol/L in men and ≥360 µmol/L in women. Analysis of covariance and multiple regression analyses were performed to study the associations between serum uric acid changes and the achieved clinic and ambulatory blood pressure during follow-up. RESULTS: ≤ 0.04) at the systolic/diastolic ranges of 130-139/≥90 mm Hg in clinic pressure, and <130/75-84 mm Hg, <145/80-84 mm Hg and <120/65-69 mm Hg in 24-h, daytime and night-time ambulatory pressure. CONCLUSION: Our study showed that antihypertensive therapy with a dihydropyridine calcium channel blocker was associated with reduced serum uric acid, especially when 24-h ambulatory systolic blood pressure was controlled.

Topics & Concepts

MedicineDihydropyridineCalcium channelUric acidInternal medicineCalciumEndocrinologyPharmacologyCardiologyGout, Hyperuricemia, Uric AcidThyroid Disorders and TreatmentsSodium Intake and Health
Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers | Litcius